Tectora Therapeutics is a biotechnology company developing oral medicines for immune-mediated diseases.
Tectora Therapeutics has raised $55.0M in total funding. The most recent round was Series A. The last funding was announced in September 2026.
Tectora Therapeutics's investors include RA Capital Management, New Enterprise Associates.
Tectora Therapeutics is headquartered in New York, United States.
Tectora Therapeutics is a biotechnology company developing oral medicines for immune-mediated diseases.
Tectora Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tectora Therapeutics — Funding & Investors." VCBacked, September 9, 2026, https://www.vcbacked.co/company/tectora-therapeutics. Accessed October 10, 2026.
VCBacked. (2026). Tectora Therapeutics — Funding & Investors. Retrieved October 10, 2026, from https://www.vcbacked.co/company/tectora-therapeutics
{{cite web |title=Tectora Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tectora-therapeutics |website=VCBacked |access-date=October 10, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated